Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of February 2024

 

Commission File Number: 001-38024

 

BeyondSpring Inc.

 

BeyondSpring Inc.

100 Campus Drive, West Side, 4th Floor, Suite 410

Florham Park, New Jersey 07932

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

---

---

On February 26, 2024, BeyondSpring Inc. (the “Company”) issued a press release announcing the receipt of notifications from the Listing Qualifications Department of The Nasdaq Stock Market LLC, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information contained in this report is hereby incorporated by reference into the Registration Statement on Form F-3, File No. 333-257639, and the Registration Statements on Form S-8, File No. 333-216639 and File No. 333-240082, of the Company.

---

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	BeyondSpring Inc.
	By:	/s/ Lan Huang

	Name: Lan Huang
	Title: Chairperson and Chief Executive Officer
Date: February 26, 2024

---

EXHIBIT INDEX

 

Exhibit No.	Exhibit
99.1	Press release, dated February 26, 2024.

 

 

---

---

Exhibit 99.1

 

BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements

 

FLORHAM PARK, N.J., February 26, 2024 – BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced that on February 20, 2024, the Company received a written notification on minimum bid price compliance (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). In the Notification Letter, the staff of Nasdaq has determined that for the 10 consecutive business days from February 5, 2024 to February 16, 2024, the closing bid price of the Company’s ordinary shares had been at $1.00 per share or greater. Accordingly, the bid price deficiency matter as previously disclosed is now closed.

 

In addition, on February 20, 2024, the Company received a written notification on periodic filing compliance (the “Letter”) from Nasdaq that it has met the periodic filing requirement for Nasdaq Listing Rule 5250(c)(2) (the “Rule”). In the Letter, the staff of Nasdaq has determined the Company complies with the Rule as the Company filed its Form 6-K for the period ended June 30, 2023 on February 2, 2024. Accordingly, the filing delinquency matter as previously disclosed is now closed.

 

About BeyondSpring

 

BeyondSpring (NASDAQ: BYSI) is a global clinical-stage biopharmaceutical company focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company is advancing its first-in-class lead asset, Plinabulin, as a direct anti-cancer agent in various cancer indications and to prevent chemotherapy-induced neutropenia. Its pipeline also includes three preclinical immuno-oncology assets. Additionally, BeyondSpring’s subsidiary, SEED Therapeutics, leverages a proprietary targeted protein degradation (TPD) drug discovery platform and has an initial R&D collaboration with Eli Lilly. Learn more by visiting https://beyondspringpharma.com.

 

Investor Contact:

 

[e-mail]

 

Media Contact:

 

[e-mail]

 

---

---